Posted 29 September, 2023
Adlai Nortye Ltd. IPO completed
IPO completed detected for ticker Nasdaq:ANL in a 424B4 filed on 29 September, 2023.
This is an initial public offering of American depositary shares, or ADSs, representing Class A ordinary shares of Adlai Nortye Ltd.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Adlai Nortye Ltd.
Health Care/Life Sciences • Pharmaceuticals
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China.Market Cap
$138M
View Company Details
$138M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.